CPI-613 is a novel lipoate analog that functions to inhibit tumor mitochondrial metabolism by simultaneously attacking the tricarboxylic acid (TCA) cycle enzymes pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (α-KGDH) [3, 7]. The gene discussed is OGDH; the disease is neoplasm.